Q-omics provides the consensus-scored EN1 profile across patient tissues and cancer cell-line models. EN1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, EN1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, EN1 RNA expression shows 14,032 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UCEC, HNSC, and BRCA as cancer lineages where EN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EN1 survival associations across molecular data types. EN1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EN1 RNA expression–survival associations across cancer types. High EN1 expression shows unfavorable associations in UCEC, KIRP, BLCA, BRCA, LGG and ACC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for EN1 RNA expression.
This table summarizes EN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for EN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EN1 shows higher tumor expression in HNSC, KIRC, BLCA, LUSC, COAD and THCA. The HNSC box plot shows higher EN1 RNA expression in tumor versus normal tissue (log2 FC = +2.990, t-test p < 0.001).
This table shows molecular features associated with EN1 in patient tissues and cancer cell lines. In patient samples, EN1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, EN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
